Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Change in Receivables (2022 - 2025)

Historic Change in Receivables for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$497000.0.

  • TriSalus Life Sciences' Change in Receivables fell 34126.21% to -$497000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $404000.0, marking a year-over-year decrease of 7827.96%. This contributed to the annual value of $1.7 million for FY2024, which is 1313.79% down from last year.
  • Per TriSalus Life Sciences' latest filing, its Change in Receivables stood at -$497000.0 for Q3 2025, which was down 34126.21% from $174000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' Change in Receivables' 5-year high stood at $940000.0 during Q3 2023, with a 5-year trough of -$736000.0 in Q4 2022.
  • In the last 4 years, TriSalus Life Sciences' Change in Receivables had a median value of $363500.0 in 2024 and averaged $250416.7.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 196571.43% in 2024, then tumbled by 34126.21% in 2025.
  • Over the past 4 years, TriSalus Life Sciences' Change in Receivables (Quarter) stood at -$736000.0 in 2022, then surged by 168.21% to $502000.0 in 2023, then dropped by 28.09% to $361000.0 in 2024, then tumbled by 237.67% to -$497000.0 in 2025.
  • Its Change in Receivables was -$497000.0 in Q3 2025, compared to $174000.0 in Q2 2025 and $366000.0 in Q1 2025.